NASDAQ$KROS
Keros Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Keros reported financial results for the quarter ended March 31, 2023.
Keros Therapeutics reported a net loss of $35.8 million in the first quarter of 2023, compared to a net loss of $24.2 million in the first quarter of 2022. The company's cash and cash equivalents totaled $351.4 million as of March 31, 2023.
- Keros is on track to report additional data from multiple clinical trials this year.
- Cash position strengthened through the sale of additional shares of common stock.
- Keros appointed Dr. Alpna Seth, Ph.D., to its board of directors in May 2023.
- Keros will present three poster abstracts from its KER-012 program at the American Thoracic Society (“ATS”) 2023 International Conference.
Headline financials
Revenue & EPS history
Keros · Revenue · Quarterly
$32K
Forward guidance
Keros expects that the cash and cash equivalents it had on hand at March 31, 2023 will enable Keros to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
+0.4%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+5.0%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+34.0%
Q3 2021
Best reaction
-15.0%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.5% | -17.4% | -15.4% | |
| Q4 2025 | -15.0% | -15.9% | -12.9% | |
| Q3 2025 | +3.4% | +8.0% | +38.6% | |
| Q1 2025 | +0.7% | +0.1% | -3.3% | |
| Q4 2024 | +0.6% | +5.9% | -1.4% | |
| Q3 2024 | +7.3% | +8.9% | +11.9% | |
| Q2 2024 | -8.9% | -8.0% | +7.7% | |
| Q1 2024 | -1.8% | -8.0% | -17.0% | |
| Q4 2023 | -3.6% | -1.4% | -5.4% | |
| Q3 2023 | -0.3% | -7.4% | +4.8% | |
| Q2 2023 | -10.3% | -12.9% | -12.9% | |
| Q1 2023 | -2.6% | -2.3% | +8.6% | |
| Q4 2022 | -6.4% | -3.6% | -23.4% | |
| Q3 2022 | -2.0% | -9.2% | +3.2% | |
| Q2 2022 | +14.7% | +13.5% | +10.6% | |
| Q1 2022 | -12.5% | -15.5% | -36.5% | |
| Q4 2021 | +8.7% | -3.5% | +29.9% | |
| Q3 2021 | +34.0% | +43.0% | +30.3% | |
| Q2 2021 | +5.5% | +2.6% | -3.7% | |
| Q1 2021 | -2.4% | -6.9% | -13.5% | |
| Q4 2020 | +4.4% | +6.6% | +14.0% | |
| Q3 2020 | -0.9% | +8.1% | +41.4% | |
| Q2 2020 | +7.1% | +12.8% | +23.6% | |
| Q1 2020 | -2.0% | +4.0% | +41.0% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro